We are live on ! Find out more
Globeflex Capital

Globeflex Capital Portfolio holdings

AUM $783M Turnover 28.73%
1-Year Est. Return 81.58%
This Fund
S&P 500
This Quarter Est. Return
+34.81%
1 Year Est. Return
+81.58%
3 Year Est. Return
+185.88%
5 Year Est. Return
+280.02%
10 Year Est. Return
+1,365.88%
AUM
$783M
AUM Growth
+$122M
Cap. Flow
-$22.1M
Cap. Flow %
-2.82%
Top 10 Hldgs %
18.08%
Holding
456
New
69
Increased
67
Reduced
73
Closed
62
Avg Time Held
1.9 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
CIEN icon
Ciena
CIEN
+$6.96M
2
MYRG icon
MYR Group
MYRG
+$4.57M
3
DRS icon
Leonardo DRS
DRS
+$4.16M
4
SMTC icon
Semtech
SMTC
+$3.99M
5
P icon
Everpure Inc
P
+$3.43M

Sector Composition

Rank Sector Weight
1 Technology 27.29%
2 Industrials 19.78%
3 Financials 17.73%
4 Healthcare 17.14%
5 Consumer Discretionary 7.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
USFD icon
451
US Foods
USFD
$22.9B
– –
-2,200
Closed -$203K –
WFRD icon
452
Weatherford International
WFRD
$6.12B
– –
-2,507
Closed -$237K –
XP icon
453
XP
XP
$7.68B
– –
-343,320
Closed -$6.54M –
GTM icon
454
ZoomInfo Technologies
GTM
$1.03B
– –
-52,010
Closed -$311K –
HTB icon
455
HomeTrust Bancshares
HTB
$743M
– –
-17,870
Closed -$762K –

Similar funds

Globeflex Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Globeflex Capital held 456 positions worth $783M, up 18% from $661M the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Globeflex Capital's Q2 2026 filing shows 69 new, 67 increased, 73 reduced and 62 closed positions. Its largest new stake was Ciena: 13,648 shares worth $6.7M. The largest sale was Catalyst Pharmaceutical, an estimated $11.2M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 23% a quarter earlier, followed by Industrials and Financials.

  • Globeflex Capital's largest Q2 2026 buy was Ciena: 13,648 shares worth $6.7M.
  • Globeflex Capital added most to MYR Group in Q2 2026, an estimated $4.57M increase.
  • Globeflex Capital's biggest Q2 2026 reduction was Rigel Pharmaceuticals, cutting an estimated $3.24M.
  • Globeflex Capital fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $11.2M.
  • Globeflex Capital's ten largest holdings make up 18% of its $783M portfolio in Q2 2026.
  • Globeflex Capital opened 69 new positions and closed 62 in Q2 2026.
  • Globeflex Capital's portfolio value rose 18% quarter-over-quarter to $783M.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.